Evidence map›Paper›PMID 31023862›Full record

ArticleThe oncologist2019

Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.

Kohei Otsubo, Kazuko Sakai, Masafumi Takeshita, Daijiro Harada, Koichi Azuma, Keiichi Ota, Hiroaki Akamatsu, Koichi Goto, Atsushi Horiike, Takayasu Kurata and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Non-small cell lung cancer withFrontiers in oncology · 2023
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kohei OtsuboResearch Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID 0000-0002-9476-8840
Kazuko SakaiDepartment of Genome Biology, Faculty of Medicine, Kindai University, Osaka, Japan.
Masafumi TakeshitaDepartment of Respiratory Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Daijiro HaradaDepartment of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Koichi AzumaDivision of Respirology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Keiichi OtaDivision of Respiratory Medicine, National Hospital Organization Fukuoka-Higashi Medical Center, Koga, Fukuoka, Japan.
Hiroaki AkamatsuThird Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Koichi GotoDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Atsushi HoriikeDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Takayasu KurataDepartment of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Osaka, Japan.
Noriaki NakagakiDepartment of Respiratory Medicine, Steel Memorial Yawata Hospital, Kitakyushu, Japan.
Kaname NosakiDepartment of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan.
Eiji IwamaResearch Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yoichi NakanishiResearch Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kazuto NishioDepartment of Genome Biology, Faculty of Medicine, Kindai University, Osaka, Japan.
Isamu OkamotoResearch Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan okamotoi@kokyu.med.kyushu-u.ac.jp.ORCID 0000-0002-7587-6096

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with non-small cell lung cancer (NSCLC) treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) eventually acquire resistance to these drugs. The identification of various resistance mechanisms for determination of subsequent treatment for these patients will require a method for simultaneous detection of multiple genetic alterations with high sensitivity. We performed cancer personalized profiling by deep sequencing (CAPP-Seq) with circulating tumor DNA obtained from patients with NSCLC who acquired resistance to first- or second-generation EGFR-TKIs. Plasma samples from 27 patients were analyzed, and 24 samples underwent CAPP-Seq successfully. Original activating

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Non-Small-Cell LungCirculating Tumor DNADNA Mutational AnalysisDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesErbB ReceptorsFeasibility StudiesFemaleGene AmplificationHigh-Throughput Nucleotide SequencingHumansLung NeoplasmsBiomarkers, TumorCirculating Tumor DNAEGFR protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesErbB ReceptorsMET protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-met

Identifiers

PMID31023862
PMCPMC6693714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.